| Name | BPHA |
| Description | BPHA (MMP-2/MMP-9 Inhibitor II) is a potent, selective and orally active inhibitor of MMP-2, MMP-9 and MMP-14 with IC50s of 12 nM, 16 nM and 17 nM, respectively.BPHA does not inhibit MMP-1, -3 and -7 (IC50s of 974, >1000 and 795 nM, respectively).BPHA has anti-angiogenic and BPHA has anti-angiogenic and anti-tumor activities. |
| In vivo | Administration of BPHA (200 mg/kg; via oral; daily) in mice effectively suppresses tumor-induced angiogenesis, primary tumor growth, and liver metastasis. BPHA exhibits remarkable growth inhibitory activity of 48% and 45% in the B16-BL6 melanoma and F2 hemangio-endothelioma models, respectively.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Methanol : 22.5 mg/mL (56.75 mM), Sonication is recommended.
DMSO : 90 mg/mL (227.01 mM), Sonication is recommended.
|
| Keywords | MMP-9 | MMP-2 | MMP-14 | BPHA |
| Inhibitors Related | Stigmasterol | Doxycycline (hyclate) | Chondroitin sulfate | Rhamnose monohydrate | Astragaloside IV | Doxycycline | Glucosamine | Meloxicam | Anethole | Propoxur | Tranexamic acid | Methylchloroisothiazolinone/Methylisothiazolinone Mixture |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Multi-Target Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
